Patent Number: 7,101,543

Title: Genetically modified cells expressing a TGF.beta. inhibitor, the cells being lung cancer cells

Abstract: The present invention relates to compositions comprising a therapeutically effective amount of genetically modified cells containing a genetic construct expressing a TGF.beta. inhibitor effective to reduce expression of TGF.beta., where the genetically modified cells are non-small cell lung cancer (NSCLC) cells or small cell lung cancer (SCLC) cells, and related methods.

Inventors: Fakhrai; Habib (La Jolla, CA)

Assignee: NovaRx

International Classification: A61K 48/00 (20060101); A61K 31/00 (20060101); A61K 47/00 (20060101)

Expiration Date: 9/05/02018